Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ TeraWulf CEO: Near-term access to power is critical (CNBC) +++ TERAWULF Aktie +3,26%

KODIAK SCIENCES Aktie

 >KODIAK SCIENCES Aktienkurs 
3.124 EUR    (Tradegate)
Ask: 3.19 EUR / 1567 Stück
Bid: 3.058 EUR / 1635 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>KODIAK SCIENCES Performance
1 Woche: -11,2%
1 Monat: +25,8%
3 Monate: -29,2%
6 Monate: -45,0%
1 Jahr: +5,9%
laufendes Jahr: -67,3%
>KODIAK SCIENCES Aktie
Name:  KODIAK SCIENCES DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US50015M1099 / A2N6P0
Symbol/ Ticker:  K27 (Frankfurt) / KOD (NASDAQ)
Kürzel:  FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD
Index:  -
Webseite:  https://kodiak.com/
Marktkapitalisierung:  164.99 Mio. EUR
Umsatz:  -
EBITDA:  -162.35 Mio. EUR
Gewinn je Aktie:  -2.678 EUR
Schulden:  60.58 Mio. EUR
Liquide Mittel:  124.37 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 1.22 / -
Gewinnm./ Eigenkapitalr.:  - / -108.92%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  KODIAK SCIENCES
Letzte Datenerhebung:  21.05.25
>Eigentümer
Aktien: 52.76 Mio. St.
f.h. Aktien: 32.35 Mio. St.
Insider Eigner: 5.52%
Instit. Eigner: 81.11%
>Peer Group

 
14.05.25 - 23:33
 Kodiak Sciences GAAP EPS of $1.09 beats by $1.99 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.05.25 - 22:18
 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results (PR Newswire)
 
PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In the first quarter of 2025, we maintained a strong focus on execution. We look forward to......
02.05.25 - 05:45
 Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases (PR Newswire)
 
PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific......
27.03.25 - 21:03
 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
 
PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor......
10.03.25 - 21:42
 Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy (PR Newswire)
 
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences......
07.01.25 - 12:03
 Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
 
PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.,......
10.12.24 - 08:06
 Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
25.11.24 - 17:18
 Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
 
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?...
14.11.24 - 23:42
 Kodiak Sciences GAAP EPS of -$0.84 beats by $0.07 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.11.24 - 22:01
 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results (PR Newswire)
 
PALO ALTO, Calif., Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief......
13.09.24 - 18:50
 Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? (Zacks)
 
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....
14.08.24 - 22:01
 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results (PR Newswire)
 
PALO ALTO, Calif., Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said......
10.07.24 - 19:33
 All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy (Zacks)
 
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
20.06.24 - 15:48
 Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? (Zacks)
 
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications....
19.06.24 - 04:01
 Insiderhandel: Vorstand verkauft Aktien von Kodiak Sciences im Wert von 7904 USD (Insiderkauf)
 
Borgeson, John A. - Vorstand - Tag der Transaktion: 2024-06-17...
14.06.24 - 18:48
 Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? (Zacks)
 
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....
14.06.24 - 02:01
 Insiderhandel: Vorstand verkauft Aktien von Kodiak Sciences im Wert von 4549 USD (Insiderkauf)
 
Borgeson, John A. - Vorstand - Tag der Transaktion: 2024-06-12...
15.05.24 - 23:19
 Kodiak Sciences Inc reports results for the quarter ended in March - Earnings Summary (Reuters EN)
 
Kodiak Sciences Inc reports results for the quarter ended in March - Earnings Summary...
15.05.24 - 23:12
 Kodiak Sciences GAAP EPS of -$0.82 beats by $0.21 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.24 - 22:01
 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results (PR Newswire)
 
PALO ALTO, Calif., May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Je höher sie steigen, je härter sie fallen. - Sprichwort Amerika
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!